A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Sponsor
Eli Lilly and Company (Industry)
Overall Status
Completed
CT.gov ID
NCT00035035
Collaborator
(none)
115

Study Details

Study Description

Brief Summary

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in your body.

    • You must have one tumor that can be physically measured or scanned by the doctor.

    • You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-FU.

    • You cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis.

    Exclusion Criteria:
    • Treatment with any medication or device that has not been approved by regulatory agencies, like the FDA, at the time you enter the study.

    • Documentation that the cancer has spread to your brain.

    • Pregnant or breastfeeding.

    • A second primary cancer.

    • Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Huntsville Alabama United States
    2 Fountain Valley California United States
    3 Fullerton California United States
    4 Lancaster California United States
    5 Los Angeles California United States
    6 Pomona California United States
    7 Santa Rosa California United States
    8 Torrance California United States
    9 Fort Collins Colorado United States
    10 Hartford Connecticut United States
    11 Lake Worth Florida United States
    12 Miami Florida United States
    13 Chicago Illinois United States
    14 Decatur Illinois United States
    15 Harvey Illinois United States
    16 Indianapolis Indiana United States
    17 Wichita Kansas United States
    18 Crestview Hills Kentucky United States
    19 Louisville Kentucky United States
    20 Lafayette Louisiana United States
    21 Shreveport Louisiana United States
    22 Scarborough Maine United States
    23 Burlington Massachusetts United States
    24 Omaha Nebraska United States
    25 Albuquerque New Mexico United States
    26 New York New York United States
    27 Canton Ohio United States
    28 Cleveland Ohio United States
    29 Drexel Hill Pennsylvania United States
    30 Pittsburgh Pennsylvania United States
    31 Charleston South Carolina United States
    32 Columbia South Carolina United States
    33 Johnson City Tennessee United States
    34 Memphis Tennessee United States
    35 Nashville Tennessee United States
    36 San Antonio Texas United States
    37 Tyler Texas United States
    38 Tacoma Washington United States
    39 Marshfield Wisconsin United States
    40 Milwaukee Wisconsin United States
    41 Capitol Federal Buenos Aires Argentina
    42 Santa Fe Rosario Argentina
    43 Ciudad De Buenos Aires Argentina
    44 Mendoza Argentina
    45 Bankstown New South Wales Australia
    46 Kingswood Penrith New South Wales Australia
    47 Wollongong New South Wales Australia
    48 Southport Queensland Australia
    49 Fitzroy Victoria Australia
    50 Frankston Victoria Australia
    51 Innsbruck Austria
    52 St. Veit Glan Austria
    53 Wien Austria
    54 Brussels Belgium
    55 Gent Belgium
    56 Leuven Belgium
    57 Cali Colombia
    58 Strasbourg Cedex France
    59 Lille Cedex France
    60 Marseille France
    61 Paris Cedex 10 France
    62 Paris Cedex 13 France
    63 Rennes Cedex France
    64 Rouen Cedex France
    65 Toulouse Cedex France
    66 Bielefeld Nordhein-Westfalen Germany
    67 Berlin Germany
    68 Bremerhaven Germany
    69 Frankfurt Germany
    70 Kaiserslautern Germany
    71 Karlsruhe Germany
    72 Magdeburg Germany
    73 Mannheim Germany
    74 Munchen Germany
    75 Neustadt/Suedharz Germany
    76 Stuttgart Germany
    77 Maroussi Athens Greece
    78 Ioannina Greece
    79 Genova Italy
    80 Ravenna Italy
    81 Roma Italy
    82 Breda Netherlands
    83 Den Haag Netherlands
    84 Enschede Netherlands
    85 Roermond Netherlands
    86 Sittard Netherlands
    87 Chiclayo Peru
    88 Lima Peru
    89 Lisboa Portugal
    90 Porto Portugal
    91 Santa Maria Da Feira Portugal
    92 Santarem Portugal
    93 Elche Alicante Spain
    94 Barcelona Spain
    95 Madrid Spain
    96 Santa Cruz De Tenerife Spain
    97 Zaragoza Spain
    98 Linkoping Sweden
    99 Lund Sweden
    100 Malmo Sweden
    101 Stockholm Sweden
    102 Umea Sweden
    103 Tao-Yuan Kuei-Shan Taiwan
    104 Yungkang City Tainan Taiwan
    105 Tainan Taiwan
    106 Taipei Taiwan
    107 Bristol Avon United Kingdom
    108 Hull East Yorkshire United Kingdom
    109 Acton London United Kingdom
    110 Northwood Middlesex United Kingdom
    111 Belfast Northern Ireland United Kingdom
    112 Manchester United Kingdom
    113 Valencia Edo. Aragua Venezuela
    114 Estado Aragua Maracay Venezuela
    115 Caracas Venezuela

    Sponsors and Collaborators

    • Eli Lilly and Company

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00035035
    Other Study ID Numbers:
    • 5148
    • H3E-MC-JMES
    • NCT00049426
    First Posted:
    May 3, 2002
    Last Update Posted:
    Jul 19, 2006
    Last Verified:
    Jul 1, 2006

    Study Results

    No Results Posted as of Jul 19, 2006